COMMUNIQUÉS West-GlobeNewswire

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
27/03/2026
ZUG, Switzerland, March 27, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to annual equity incentive awards granted to a member of the executive committee of the Company. Attachment notification-of-managers [...]
Crescent Biopharma Announces Grants of Inducement Awards
27/03/2026
WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies [...]
Preliminary Results for the Year Ended 31 December 2025
27/03/2026
March 27, 2026 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX [...]
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
27/03/2026
BRISBANE, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on March 23, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera [...]
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights
27/03/2026
Announced partnership with Australian CRO to accelerate initiation of CLD-401 clinical trial The Company has received feedback from the FDA through Type D interactions, and the Company believes its manufacturing and [...]
BiomX Inc. Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency
27/03/2026
Discloses “Going Concern” Explanatory Paragraph in Auditor’s Report NETANYA, Israel, March 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (the “Company”) today announced that on March 25, 2026, the [...]
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
27/03/2026
EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – FDA Type A endpoint alignment in July 2025, Phase 3 protocol submitted to the FDA with comments expected in [...]
Cue Biopharma Announces CEO Transition
27/03/2026
Lucinda Warren Appointed Interim President and Chief Executive Officer – Usman Azam Steps Down BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company [...]
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
27/03/2026
WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with [...]
Leo International Precision Health AG: Mr Leo Wang, Acquisition
27/03/2026
Leo International Precision Health AG: Mr Leo Wang, Acquisition Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them, 27. Mar [...]
NTG Nordic Transport Group A/S – Annual General Meeting 2026
27/03/2026
Company announcement no. 7 – 26 27 March 2026 NTG Nordic Transport Group A/S – Annual General Meeting 2026 Today, at 14:00, NTG Nordic Transport Group A/S (“NTG” or the “Company”), CVR no. 12 54 61 06, held its Annual [...]
Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138
27/03/2026
- Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Measures including Disease Severity, Itch, and Quality of Life - WAYNE, Pa., March 27, 2026 (GLOBE NEWSWIRE) -- Aclaris [...]
Jushi Holdings Inc. Refinances Former 1st Lien Credit Facility and Former 2nd Lien Credit Facility with US$160 Million Non-Dilutive Debt Financing
27/03/2026
Adds Cash to the Balance Sheet The Company to Report Fourth Quarter 2025 Financial Results on March 31, 2026 BOCA RATON, Fla., March 27, 2026 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH [...]
EUROAPI - Mise à disposition du Document d’Enregistrement Universel 2025
27/03/2026
Communiqué de presse Mise à disposition du Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel Paris - Le 27 mars 2026 - EUROAPI annonce la publication de son Document d’Enregistrement [...]
LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
27/03/2026
Multiple SIRS presentations underscore the potential of LB-102 to address positive, negative, and cognitive symptom domains of schizophrenia NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB [...]
Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
27/03/2026
SOLANA BEACH, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 3,188,407 [...]
EUROAPI - Availability of the 2025 Universal Registration Document
27/03/2026
Press Release Availability of the 2025 Universal Registration Document, including the Annual Financial Report Paris – March 27, 2026 – EUROAPI announces the publication of its 2025 Universal Registration Document in [...]
Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting
27/03/2026
Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to optimize dermal bioavailability of rapamycin for mTOR-driven skin diseases while overcoming the crystallization, stability [...]
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
27/03/2026
- Improvements seen across all six DLQI Domains indicating broad, beneficial impact on quality of life - - Data further d emonstrates first-in-class and best-in-disease barzolvolimab profile - HAMPTON, N.J., March 27, [...]

Pages